Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout investments, has appointed Amit Karna as Senior Director and Carlo Cartapani as Analyst.
Karna brings more than 15 years of finance experience across both the USA and Europe, notably in the Healthcare sector, while Carlo has a strong background in Corporate Finance.
Prior to joining Keensight Capital, Karna spent 10 years in the Investment Banking Division of Goldman Sachs, first in New York and then in London. As part of the Global Healthcare Group, he handled numerous mid & large-cap transactions, across a range of healthcare sectors, including the sale of Sonion to Novo Holdings, Werfen’s sale of Bolton Medical to Terumo, the carve-out of a global consumer healthcare portfolio for GlaxoSmithKline, the sale of Carlyle’s stake in Medical Park to Turkven, and the sale of Baxter Healthcare’s US injectables business to Hikma.
Karna started his career in New York at Manufacturers & Traders Trust, where he held various positions in portfolio Risk Management. He also founded and led Daten Capital LLP, a London-based firm leveraging AI to invest in the Pharma industry.
A US citizen, Karna graduated from Bowdoin College with a BA in Biology, holds an MBA from Columbia University in New York, and is a CFA Charterholder.
Cartapani began his career in 2016 in the International Affairs team at Cap Digital, a European business cluster for digital transformation. He then joined Eurvad Finance, a boutique specialized in small & mid-cap transactions, as an M&A Analyst.
From Italy, Cartapani graduated from ESSEC Business School and holds a bachelor’s degree in Economics and Management from the University of Trento.
